| Name | Title | Contact Details |
|---|
Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.
We offer bariatric and non-bariatric medical equipment including bed frames, therapeutic mattresses, and mobility items for patients of all ages.
EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...
The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.